Why Is OPKO HEALTH INC (OPK) Stock Up Today?

OPKO Health shares surged 17.52% to close at $1.61 on October 15, 2026. The primary driver was the announcement that Labcorp has agreed to acquire select assets from OPKO’s BioReference Health subsidiary, a move that includes the FDA-approved 4Kscore Test.

What Happened

OPKO Health filed an 8-K with the SEC disclosing the entry into a material definitive agreement with Labcorp. Under the terms of the deal, Labcorp will pay $722 million in cash for more than 80 patient service centers and the 4Kscore Test. The agreement also includes a potential earnout of up to $150 million based on future revenue performance, bringing the total potential value of the transaction to $872 million. This acquisition allows Labcorp to expand its access to clinical laboratory services and a broad specialty testing menu for patients and providers nationwide.

What The Data Shows

The stock’s market capitalization stands at $985.2 million. Fundamentals indicate the company is currently unprofitable, with a trailing twelve-month EPS of negative $0.09 and a net margin of negative 12.4%. Revenue has declined 11.5% over the same period. The stock carries a beta of 1.50, suggesting higher volatility relative to the broader market. Over the last 8 sessions prior to the jump, the stock had moved up 7.7% from $1.46 to $1.57. The 52-week range for OPK is $0.98 to $1.75. On the day of the announcement, the stock printed three fresh 52-week highs and seven fresh 52-week lows.

What To Watch

Investors will monitor the completion of the asset transfer and the subsequent impact on OPKO’s remaining operations. The company’s unprofitable status and declining revenue trend remain key factors as it transitions away from the diagnostics business.